Mitotic DNA synthesis is caused by transcription-replication conflicts in BRCA2-deficient cells.


Journal

Molecular cell
ISSN: 1097-4164
Titre abrégé: Mol Cell
Pays: United States
ID NLM: 9802571

Informations de publication

Date de publication:
15 09 2022
Historique:
received: 15 02 2022
revised: 31 05 2022
accepted: 16 07 2022
pubmed: 25 8 2022
medline: 21 9 2022
entrez: 24 8 2022
Statut: ppublish

Résumé

Aberrant replication causes cells lacking BRCA2 to enter mitosis with under-replicated DNA, which activates a repair mechanism known as mitotic DNA synthesis (MiDAS). Here, we identify genome-wide the sites where MiDAS reactions occur when BRCA2 is abrogated. High-resolution profiling revealed that these sites are different from MiDAS at aphidicolin-induced common fragile sites in that they map to genomic regions replicating in the early S-phase, which are close to early-firing replication origins, are highly transcribed, and display R-loop-forming potential. Both transcription inhibition in early S-phase and RNaseH1 overexpression reduced MiDAS in BRCA2-deficient cells, indicating that transcription-replication conflicts (TRCs) and R-loops are the source of MiDAS. Importantly, the MiDAS sites identified in BRCA2-deficient cells also represent hotspots for genomic rearrangements in BRCA2-mutated breast tumors. Thus, our work provides a mechanism for how tumor-predisposing BRCA2 inactivation links transcription-induced DNA damage with mitotic DNA repair to fuel the genomic instability characteristic of cancer cells.

Identifiants

pubmed: 36002001
pii: S1097-2765(22)00707-9
doi: 10.1016/j.molcel.2022.07.011
pmc: PMC9631240
pii:
doi:

Substances chimiques

BRCA2 Protein 0
BRCA2 protein, human 0
Aphidicolin 38966-21-1
DNA 9007-49-2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3382-3397.e7

Subventions

Organisme : Wellcome Trust
ID : 203141/Z/16/Z
Pays : United Kingdom
Organisme : Cancer Research UK
ID : DRCPGM\100001
Pays : United Kingdom
Organisme : Cancer Research UK
ID : C29215/A20772
Pays : United Kingdom

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests T.D.H. has a part-time position as Chief Scientific Officer of FoRx Therapeutics, AG.

Références

J Cell Biol. 2011 Apr 4;193(1):97-108
pubmed: 21444690
Mol Cell. 2001 Feb;7(2):263-72
pubmed: 11239455
J Cell Biol. 2017 Dec 4;216(12):3991-4005
pubmed: 29042409
Nat Commun. 2019 Jan 8;10(1):87
pubmed: 30622252
Genome Res. 2013 Oct;23(10):1590-600
pubmed: 23868195
FEBS J. 2009 Mar;276(6):1494-505
pubmed: 19228196
Nature. 2011 Feb 3;470(7332):120-3
pubmed: 21258320
Nucleic Acids Res. 2020 Aug 20;48(14):e84
pubmed: 32544226
Nat Struct Mol Biol. 2016 Aug;23(8):714-21
pubmed: 27348077
Cell Rep. 2018 Jan 23;22(4):1031-1039
pubmed: 29386125
Mol Cell. 2019 Feb 21;73(4):670-683.e12
pubmed: 30639241
EMBO J. 2021 Apr 1;40(7):e106018
pubmed: 33634895
Genome Res. 2015 Feb;25(2):189-200
pubmed: 25373142
Nat Commun. 2021 Aug 13;12(1):4919
pubmed: 34389725
Mol Cell. 2016 Dec 15;64(6):1127-1134
pubmed: 27984746
J Cell Biol. 2000 Dec 25;151(7):1381-90
pubmed: 11134068
Science. 1992 Nov 27;258(5087):1463-6
pubmed: 1279808
Nat Cell Biol. 2011 Mar;13(3):243-53
pubmed: 21317883
Nature. 2016 Jul 20;535(7612):382-7
pubmed: 27443740
Nucleic Acids Res. 2022 Feb 28;50(4):2051-2073
pubmed: 35100392
Nucleic Acids Res. 2016 Jul 8;44(W1):W160-5
pubmed: 27079975
Mol Cell. 2017 Jun 15;66(6):801-817
pubmed: 28622525
Nature. 2014 Jul 17;511(7509):362-5
pubmed: 24896180
Nat Cell Biol. 2019 Apr;21(4):487-497
pubmed: 30804506
Cell Res. 2020 Nov;30(11):997-1008
pubmed: 32561860
Nat Commun. 2017 Jul 17;8:15983
pubmed: 28714477
Nucleic Acids Res. 2020 Jun 4;48(10):5467-5484
pubmed: 32329774
Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):686-91
pubmed: 21148102
Nat Struct Mol Biol. 2017 Apr;24(4):353-361
pubmed: 28263325
Mol Cell. 2011 Jun 24;42(6):794-805
pubmed: 21700224
DNA Repair (Amst). 2014 Jul;19:84-94
pubmed: 24746923
Cell. 2019 Oct 17;179(3):604-618
pubmed: 31607512
Proc Natl Acad Sci U S A. 2019 Jan 15;116(3):816-825
pubmed: 30591567
Nat Struct Mol Biol. 2011 Nov 06;18(12):1421-3
pubmed: 22056772
Nat Commun. 2017 Sep 13;8(1):525
pubmed: 28904335
Cell. 2013 Nov 21;155(5):1088-103
pubmed: 24267891
J Cell Biol. 2021 Sep 6;220(9):
pubmed: 34232287
PLoS Genet. 2014 May 01;10(5):e1004318
pubmed: 24787137
Nature. 2016 May 02;534(7605):47-54
pubmed: 27135926
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Mol Cell. 2014 Dec 18;56(6):777-85
pubmed: 25435140
Mol Cell Biol. 2010 Jan;30(1):146-59
pubmed: 19841062
Nat Biotechnol. 2015 Aug;33(8):877-81
pubmed: 26192317
Genes Dev. 1996 Aug 15;10(16):2025-37
pubmed: 8769646
Cell. 2017 Aug 10;170(4):787-799.e18
pubmed: 28802046
Nat Rev Cancer. 2017 Jul 25;17(8):489-501
pubmed: 28740117
Nature. 2015 Feb 12;518(7538):258-62
pubmed: 25642963
Mol Cell. 2015 Feb 19;57(4):636-647
pubmed: 25699710
Nat Commun. 2017 Oct 16;8(1):860
pubmed: 29038425
PLoS Genet. 2011 Dec;7(12):e1002386
pubmed: 22144908
Hum Mol Genet. 1998 Apr;7(4):755-61
pubmed: 9499431
Nat Immunol. 2003 May;4(5):442-51
pubmed: 12679812
Genes Dev. 2011 Oct 1;25(19):2041-56
pubmed: 21979917
Genes Chromosomes Cancer. 2019 May;58(5):305-316
pubmed: 30387289
Mol Cell. 2020 Feb 6;77(3):528-541.e8
pubmed: 31759821
Mol Cell. 2019 Feb 7;73(3):398-411
pubmed: 30735654
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Cold Spring Harb Perspect Biol. 2013 Dec 01;5(12):a010397
pubmed: 23881940
Cell. 2011 May 13;145(4):529-42
pubmed: 21565612
Mol Cell Biol. 2013 Jan;33(2):406-17
pubmed: 23149945
Nat Commun. 2016 Jan 11;7:10208
pubmed: 26751768
Chem Biol. 2015 Nov 19;22(11):1491-1504
pubmed: 26548611
Mol Cell. 2022 Jun 16;82(12):2267-2297
pubmed: 35508167
Trends Genet. 2012 Jan;28(1):22-32
pubmed: 22094264
Hum Genet. 1984;67(2):136-42
pubmed: 6430783
Cell. 2016 Dec 1;167(6):1455-1467
pubmed: 27912056
Nature. 2015 Dec 10;528(7581):286-90
pubmed: 26633632
Trends Cell Biol. 2009 Aug;19(8):414-22
pubmed: 19589679
Nature. 2016 Jul 7;535(7610):178-81
pubmed: 27362223
Nature. 2018 Mar 1;555(7694):112-116
pubmed: 29466339
Mol Cell. 2016 Dec 15;64(6):1117-1126
pubmed: 27984745
Mol Cell. 2016 Feb 4;61(3):449-460
pubmed: 26748828
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
Cell. 2017 Aug 10;170(4):774-786.e19
pubmed: 28802045
Nat Cell Biol. 2014 Jan;16(1):2-9
pubmed: 24366029
Nat Rev Mol Cell Biol. 2016 Sep;17(9):553-63
pubmed: 27435505
Nature. 2021 Jun;594(7862):283-288
pubmed: 33981036
Cell Res. 2008 Jan;18(1):99-113
pubmed: 18166982

Auteurs

Florian J Groelly (FJ)

Genome Stability and Tumourigenesis Group, Department of Oncology, Oxford Institute for Radiation Oncology, University of Oxford, Oxford OX3 7DQ, UK.

Rebecca A Dagg (RA)

Genome Stability and Tumourigenesis Group, Department of Oncology, Oxford Institute for Radiation Oncology, University of Oxford, Oxford OX3 7DQ, UK.

Michalis Petropoulos (M)

Department of Molecular Biology, University of Geneva, 1205 Geneva, Switzerland.

Giacomo G Rossetti (GG)

Department of Molecular Biology, University of Geneva, 1205 Geneva, Switzerland.

Birbal Prasad (B)

Genome Stability and Tumourigenesis Group, Department of Oncology, Oxford Institute for Radiation Oncology, University of Oxford, Oxford OX3 7DQ, UK.

Andreas Panagopoulos (A)

Department of Molecular Mechanisms of Disease, University of Zurich, 8057 Zurich, Switzerland.

Teressa Paulsen (T)

Genome Stability and Tumourigenesis Group, Department of Oncology, Oxford Institute for Radiation Oncology, University of Oxford, Oxford OX3 7DQ, UK.

Angeliki Karamichali (A)

Department of Molecular Biology, University of Geneva, 1205 Geneva, Switzerland.

Samuel E Jones (SE)

Department of Oncology, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK.

Fena Ochs (F)

Department of Biochemistry, University of Oxford, South Parks Road, Oxford OX1 3QU, UK.

Vasilis S Dionellis (VS)

Department of Molecular Biology, University of Geneva, 1205 Geneva, Switzerland.

Emilia Puig Lombardi (E)

Genome Stability and Tumourigenesis Group, Department of Oncology, Oxford Institute for Radiation Oncology, University of Oxford, Oxford OX3 7DQ, UK.

Matthieu J Miossec (MJ)

Bioinformatics and Statistical Genetics Core, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK.

Helen Lockstone (H)

Bioinformatics and Statistical Genetics Core, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK.

Gaëlle Legube (G)

LBCMCP, Centre de Biologie Intégrative (CBI), CNRS, Université de Toulouse, UT3, Toulouse 31062, France.

Andrew N Blackford (AN)

Department of Oncology, MRC Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Oxford OX3 9DS, UK.

Matthias Altmeyer (M)

Department of Molecular Mechanisms of Disease, University of Zurich, 8057 Zurich, Switzerland.

Thanos D Halazonetis (TD)

Department of Molecular Biology, University of Geneva, 1205 Geneva, Switzerland. Electronic address: thanos.halazonetis@unige.ch.

Madalena Tarsounas (M)

Genome Stability and Tumourigenesis Group, Department of Oncology, Oxford Institute for Radiation Oncology, University of Oxford, Oxford OX3 7DQ, UK. Electronic address: madalena.tarsounas@oncology.ox.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH